Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility

AUTOR(ES)

Valenzuela B., M. Teresa, Altuzarra H., Rogelio, Trucco A., Olivia, Villegas R., Rodrigo, Inostroza S., Jaime, Granata S., Paulo, Fleiderman V., José, Maggi C., Leonardo

FONTE

Brazilian Journal of Infectious Diseases

DATA DE PUBLICAÇÃO

2007-06

RESUMO

S. pneumoniae is a significant cause of community-acquired pneumonia in the elderly, and accounts for the majority of the pneumonia deaths among the elderly. We conducted this randomized double-blind study to evaluate the immune response to a 23-valent pneumococcal polysaccharide vaccine and the persistence of antibodies two years after the vaccination in an elderly population in Santiago, Chile. A total of 118 elderly nursing home residents received either the pneumococcal or a tetanus control vaccine. Serum samples were taken at enrolment, at two months, and at two years post-vaccination. Pre-vaccination anti-pneumococcal antibody geometric mean concentrations (GMC) were similar in both study groups, with increased levels of antibodies found only against serotype 14. The pneumococcal vaccine was highly immunogenic at 2 months, and titers remained high two years after the vaccination for the 10 serotypes studied in this elderly population. The results thus support the benefits of this pneumococcal vaccine in this elderly population who are at increased risk of invasive pneumococcal disease.

Documentos Relacionados

• Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly
• Immunogenicity and Tolerance of a 7-Valent Pneumococcal Conjugate Vaccine in Nonresponders to the 23-Valent Pneumococcal Vaccine
• Assessment of pharmacotherapeutic safety of medical prescriptions for elderly residents in a long-term care facility
• Anemia in elderly residents of a long-term care institution
• Pill-splitting in a long-term care facility